• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    11/14/23 3:17:16 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email
    SC 13D/A 1 sc13da209076057_11142023.htm AMENDMENT NO. 2 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 2)1

    LifeVantage Corporation

    (Name of Issuer)

    Common Stock, par value $0.0001

    (Title of Class of Securities)

    53222K205

    (CUSIP Number)

    BRADLEY L. RADOFF

    2727 Kirby Drive

    Unit 29L

    Houston, Texas 77098

     

    RYAN NEBEL

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    November 10, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 53222K205

      1   NAME OF REPORTING PERSON  
             
            The Radoff Family Foundation  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            TEXAS  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         50,000  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              50,000  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            50,000  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%  
      14   TYPE OF REPORTING PERSON  
             
            CO  

      

    2

    CUSIP No. 53222K205

      1   NAME OF REPORTING PERSON  
             
            Bradley L. Radoff  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            PF, AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         861,250  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              861,250  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            861,250  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.8%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    3

    CUSIP No. 53222K205

     

      1   NAME OF REPORTING PERSON  
             
            Michael Lohner  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☒
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
             
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            0%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    4

    CUSIP No. 53222K205

     

    The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned (“Amendment No. 2”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.

    Item 2.Identity and Background.

    Item 2 is hereby amended to add the following:

    As previously disclosed, on August 9, 2023, (i) Bradley L. Radoff and The Radoff Family Foundation (collectively, “Radoff”), (ii) Sudbury Capital Fund, LP, Sudbury Holdings, LLC, Sudbury Capital GP, LP, Sudbury Capital Management, LLC and Dayton Judd (collectively, “Sudbury”) and (iii) Michael Lohner entered into a Joint Filing and Solicitation Agreement (the “Original Agreement”) for the purpose of, among other things, working together to enhance stockholder value at the Issuer, including by seeking representation on the Board of Directors of the Issuer at the fiscal year 2024 annual meeting of stockholders of the Issuer (the “Fiscal 2024 Annual Meeting”). Pursuant to its terms, the Original Agreement was scheduled to terminate upon the earlier to occur of the (i) certification of the results of the Fiscal 2024 Annual Meeting and (ii) written agreement of Radoff and Sudbury. Prior to the certification of the results of the Fiscal 2024 Annual Meeting, Radoff and Sudbury determined to continue to work together to enhance stockholder value and improve corporate governance at the Issuer. In connection therewith, on November 10, 2023, Radoff and Sudbury entered into the Group Agreement (as defined and further described in Item 4). As a result, Radoff may continue to be deemed to be a member of a “group,” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), comprised of Radoff and Sudbury. It is the understanding of Radoff that Sudbury will file a separate Schedule 13D with respect to its ownership of Shares pursuant to Rule 13d-1(k)(2) of the Exchange Act. Reference is made to such Schedule 13D for information concerning Sudbury and its investment in the Issuer. Michael Lohner is no longer a member of the Section 13(d) group and shall cease to be a Reporting Person immediately upon the filing of this Amendment No. 2.

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and restated to read as follows:

    The Shares purchased by the Radoff Foundation were purchased with working capital. The aggregate purchase price of the 50,000 Shares directly owned by the Radoff Foundation is approximately $222,204, including brokerage commissions.

    The Shares directly owned by Mr. Radoff were purchased with personal funds. The aggregate purchase price of the 811,250 Shares directly owned by Mr. Radoff is approximately $3,173,375, including brokerage commissions.

    Item 4.Purpose of Transaction.

    Item 4 is hereby amended to add the following:

    Prior to the certification of the results of the Fiscal 2024 Annual Meeting on November 10, 2023, Radoff and Sudbury determined to continue to work together and in connection therewith entered into a group agreement (the “Group Agreement”) to supersede the Original Agreement for the purposes of working together to (i) enhance stockholder value and improve corporate governance at the Issuer, (ii) take all other action necessary to achieve the foregoing and (iii) take any other actions they determine to undertake in connection with their respective investment in the Issuer. The foregoing description of the Group Agreement does not purport to be complete and is subject to and is qualified in its entirety by reference to the full text of the Group Agreement, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

    5

    CUSIP No. 53222K205

    On November 13, 2023, counsel to Radoff and Sudbury delivered a letter to counsel to the Issuer (the “Document Preservation Notice”) notifying the Issuer of its obligations to take reasonable steps to preserve and retain all documents, including electronically stored information, in connection with Radoff and Sudbury (i) exploring potential claims that the Issuer’s directors took steps to unlawfully entrench themselves in violation of their fiduciary duties to the Issuer’s stockholders, and (ii) investigating and potentially filing various claims regarding potential violations of securities laws by the Issuer, in particular Section 14(a) of the Exchange Act, in connection with the Fiscal 2024 Annual Meeting. The foregoing description of the Document Preservation Notice does not purport to be complete and is subject to and is qualified in its entirety by reference to the full text of the Document Preservation Notice, a copy of which is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

    Item 5.Interest in Securities of the Issuer.

    Items 5(a) - (c) are hereby amended and restated to read as follows:

    The aggregate percentage of Shares reported owned by each person named herein is based upon 12,713,887 Shares outstanding as of November 8, 2023, which is the total number of Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

    A.The Radoff Foundation

    (a)       As of the date hereof, the Radoff Foundation beneficially owns directly 50,000 Shares.

    Percentage: Less than 1%

    (b)1. Sole power to vote or direct vote: 50,000
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 50,000
    4. Shared power to dispose or direct the disposition: 0

     

    B.Mr. Radoff
    (a)As of the date hereof, Mr. Radoff beneficially owns directly 811,250 Shares. As a director of the Radoff Foundation, Mr. Radoff may be deemed to beneficially own the 50,000 Shares owned by the Radoff Foundation.

    Percentage: Approximately 6.8%

    (b)1. Sole power to vote or direct vote: 861,250
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 861,250
    4. Shared power to dispose or direct the disposition: 0
    C.Mr. Lohner
    (a)As of the date hereof, Mr. Lohner beneficially owns 0 Shares.

    6

    CUSIP No. 53222K205

    Percentage: 0%

    (b)1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: 0

    Sudbury has represented to Radoff that it beneficially owns 762,741 Shares. Collectively, Sudbury and Radoff beneficially own 1,623,991 Shares, which represents approximately 12.8% of the outstanding Shares. Each Reporting Person disclaims beneficial ownership of the Shares that he or it does not directly own. Furthermore, the Reporting Persons expressly disclaim beneficial ownership of the 762,741 Shares beneficially owned by Sudbury.

    (c)       There have been no transactions in securities of the Issuer by the Reporting Persons during the past 60 days.

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 is hereby amended to add the following:

    Prior to the certification of the results of the Fiscal 2024 Annual Meeting on November 10, 2023, Radoff and Sudbury entered into the Group Agreement, as defined and described in Item 4 above and attached as Exhibit 99.1 hereto.

     

    Item 7.Material to be Filed as Exhibits.

    Item 7 is hereby amended to add the following exhibits:

     

    99.1Group Agreement, dated November 10, 2023.
    99.2Document Preservation Notice, dated November 13, 2023.
    7

    CUSIP No. 53222K205

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2023

      The Radoff Family Foundation
       
      By:

    /s/ Bradley L. Radoff

        Name: Bradley L. Radoff
        Title: Director

     

     

     

    /s/ Bradley L. Radoff

     

    Bradley L. Radoff

    Individually and as attorney-in-fact for Michael Lohner

     

    8

     

    Get the next $LFVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Lifevantage with a new price target

      Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

      1/14/25 8:36:52 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Lifevantage with a new price target

      Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

      12/19/24 8:39:43 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lewis Darwin bought $4,873 worth of shares (379 units at $12.86), increasing direct ownership by 0.33% to 116,767 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      6/17/25 4:11:27 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mauro Garry Paul bought $26,338 worth of shares (2,150 units at $12.25), increasing direct ownership by 0.70% to 86,087 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      5/13/25 4:11:14 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lewis Darwin bought $3,632 worth of shares (227 units at $16.00), increasing direct ownership by 0.20% to 116,388 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      12/17/24 5:00:17 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    SEC Filings

    See more
    • Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:06:34 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      5/6/25 4:05:28 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifevantage Corporation

      10-Q - Lifevantage Corp (0000849146) (Filer)

      2/5/25 4:05:56 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Global Convention 2025 Empowers Consultants to 'Go Further' with Exclusive Trainings, Product Announcements, and New Incentives to Drive Growth

      SALT LAKE CITY, April 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of their annual Global Convention, held April 24-26, 2025, in Salt Lake City, Utah. Thousands of independent LifeVantage Consultants from around the world gathered at the Salt Palace Convention Center to participate in the multi-day event. Attendees heard from a variety of LifeVantage executives and speakers on key business updates, exciting product announcements, exclusive business and compensation plan trainings, and initiatives designed

      4/28/25 8:00:00 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care